Oral Presentation Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Breast Cancer in 2016: where to from here? (#1)

Shom Goel 1
  1. Dana-Farber Cancer Institute (DFCI), and Harvard Medical School, Boston, United States

Over the last decade, several incremental advances have been made in systemic therapy of metastatic breast cancer. Novel endocrine agents, anti-HER2 therapies, targeted therapies, and even cytotoxics have entered routine clinical practice over this time, each offering a different degree of clinical benefit. Standing upon this foundation, we are now facing waves of new information pertaining to tumor immunology and genomics. In this presentation, I will discuss how these new insights might be integrated into our existing knowledge to develop more successful therapeutic strategies.